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Background: To examine an association between self-reported sleep quality determined by Pittsburgh sleep quality
index (PSQI) and metabolic syndrome.
Methods: This study was designed as cross-sectional study. Participants were 1481 adults aged 20 years and above
from general population (549 males and 932 females). We assessed the global sleep quality by PSQI. PSQI consists
of 7 elements, i.e. subjective sleep quality, sleep latency (prolonged sleep onset time), sleep duration, habitual sleep
efficiency (proportion of hours slept to hours spent in bed), sleep disturbance (interruption of sleep), use of sleep
medication and daytime dysfunction (trouble staying awake while engaging in social activity). Any participants with
score of 6 or more are diagnosed to have sleep disorder. We also assessed the above 7 elements, which consisted
of a four-grade system (i.e. 0, 1, 2, 3). Metabolic syndrome consisted of abdominal obesity, hypertension, impaired
glucose tolerance and dyslipidemia. Diagnosis of metabolic syndrome was done when the participants have
abdominal obesity and meet two or more other components. All analyses were adjusted by age, drinking habit,
smoking habit, working hours, exercise habit and depression.
Results: Fifty-two male participants (9.5%) and 133 female (14.3%) scored 6 or more points in global PSQI score. The
global PSQI score, sleep latency score and sleep disturbance score of participants with metabolic syndrome were higher
level than those without the condition (p < 0.001, p = 0.009, p = 0.025 for male and p < 0.001, p < 0.001, p = 0.002 for
females, respectively). The odds ratio of metabolic syndrome among participants with PSQI score of 6 or more points
were 2.37 (95% confidence interval: 1.23-4.58) for males and 2.71 (1.45-5.07) for females in contrast to those with 5 or less
points. The odds ratio of metabolic syndrome with sleep latency score of 2 was 2.65 (1.14-6.15) for male and 3.82
(1.81-8.09) for females in contrast with those of 0. The odds ratio of metabolic syndrome with sleep disturbance score of 1
was 1.76 (1.09-2.86) for males and 2.43 (1.26-4.69) for females in contrast with those of 0.
Conclusions: Global PSQI score and its components (especially, sleep latency and sleep disturbance) were associated
with metabolic syndrome.
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Metabolic syndrome, which consists of a complex com-
bination of abdominal obesity, hypertension, impaired glu-
cose tolerance and dyslipidemia is a large health problem
around the world. This medical disorder increases mor-
bidity and mortality of cardiovascular diseases and stroke,
for it raises risks of atherosclerosis [1-3]. To decrease the* Correspondence: nakaji@cc.hirosaki-u.ac.jp
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unless otherwise stated.mortality or morbidity of cardiovascular diseases and
stroke, it is important to prevent and to improve their risk
factors including metabolic syndrome. It has been thought
that metabolic syndrome is caused by a nutrient imbal-
ance with impaired eating habits and low consumption of
calories due to lack of exercise. Thus, various public orga-
nizations and medical institutions have been providing ad-
vice to encourage appropriate dietary intake and physical
exercise to the public.
Associations of sleep duration with obesity, diabetes
mellitus, hypertension, atherosclerosis and cardiovascularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Okubo et al. BMC Public Health 2014, 14:562 Page 2 of 7
http://www.biomedcentral.com/1471-2458/14/562diseases have been reported [4-8]. A role of sleep is not
only rest of body but also suppression of blood pressure
and glucose tolerance by decreasing the secretion of cat-
echolamine and cortisol [9], which then leads to preven-
tion of metabolic syndrome and other obesity-related
diseases.
Hall et al. have reported that those who have slept 7 to
8 hours per night have had the lowest morbidity of meta-
bolic syndrome, and those who have slept longer or shorter
have shown an increase risk of metabolic syndrome (the
so-called U-shaped associations) [10]. Moreover, short and
long sleep duration has been associated with higher mortal-
ity of cardiovascular diseases [11,12]. However, assessment
of sleep only by its duration is not enough. Some previous
studies have suggested that status of sleep has quantitative
and qualitative aspects [13,14]. Actually, some studies have
reported that sleep quality is associated with overweight
and metabolic syndrome [15,16], but the limited number of
the studies cannot provide good evidence of it. Also, insuffi-
cient adjustment of confounding factors such as gender
and lifestyles including drinking and exercise habit also give
us controversy.
For better evidence, we analyzed data separately by gen-
der and adjusted by age, and other plausible confounding
factors to examine the relationship of sleep and its compo-




Participants were 1552 individuals from the general popu-
lation who participated in the Iwaki Health Promotion
Project from 2007 to 2010 in Aomori Prefecture, located
in northern Japan. The project was a screening project for
the residents, and this study was designed as a population-
based cross-sectional research. Any participants with
missing data, steroid intake, clinical history of malignant
diseases or psychotic illness were excluded from the study.
Thus, the number of participants who were eligible for
statistical analysis included 1481 participants (549 males
and 932 females). Ages of the participants were between
20 and 80 years old. The contents and purpose of this
study were thoroughly explained to the participants prior
to the study, and written consent was obtained from all of
the participants.
Approval for the study was obtained from the Ethics
Committee of Hirosaki University Graduate School of
Medicine.
Measures and definitions
Self-reported questionnaires were sent to the participants
prior to the investigation and were collected on the day of
investigation. In the questionnaires, participants were
asked about their gender, age, smoking habit, drinkinghabit, exercise habit, working hours per week, PSQI, pres-
ence of depression, medical history of malignant diseases
or psychotic illness and any medications which they are
currently taking (hypnotic drugs, steroid, antidyslipidemic
drugs, antihypertensive drugs, antidiabetic drugs). We used
the Center for Epidemiologic Studies Depression (CES-D)
scale for an index of depression. CES-D scale was estab-
lished in 1977 by Radloff to evaluate presence and grades of
depression. It consists of twenty items with sixty points as a
perfect score, and those who scored more than sixteen
points are diagnosed to be depressive [17]. Exercise habit
was determined whether or not they exercised regularly.
Working hours per week included that of main job and of
added job.
We assessed sleep quality of the participants by the Pitts-
burgh Sleep Quality Index (PSQI) scale [18]. It is a widely
used measure of sleep quality and is well validated, reliable
and readily completed by most individuals. PSQI consists
of 7 elements: subjective sleep quality (a subjective feeling
of satisfaction at daily sleep), sleep latency (prolonged sleep
onset time), sleep duration, habitual sleep efficiency (pro-
portion of hours slept to total hours in bed), sleep disturb-
ance (interruption of sleep), use of sleep medication, and
daytime dysfunction (trouble staying awake while engaging
in social activity) with total score of 21. Any participants
with score of 6 or more are diagnosed to have sleep dis-
order [18]. We assessed not only global PSQI score but also
the above 7 components, which consisted of the four-grade
system (i.e. 0, 1, 2, 3) [18]. Subjective sleep quality was
assessed 0–3 points (0 - very good sleep quality; 1 - fairly
good sleep quality; 2 - fairly bad sleep quality; 3 - very bad
sleep quality). Sleep latency was assessed 0–3 points (mi-
nutes required to go to sleep each night and frequency of
getting to sleep within 30 minutes). Sleep duration was
assessed 0–3 points (0 - sleep duration >7 hours; 1 -
6- ≤ 7 hours; 2 - 5- < 6 hours; 3 - <5 hours). Habitual
sleep efficiency was assessed 0-3points (proportion of
hours slept to hours spent in bed, 0 - ≥85%; 1 - 75-
84%; 2 - 65-74%; 3 - <65%). Sleep disturbance was
assessed 0-3points (having trouble sleeping because of
some reasons and the frequency of those). Use of sleep
medication was assessed 0-3points (0 - not use during the
past month; 1 - less than once a week; 2 - once or twice a
week; 3 - three or more times a week). Daytime dysfunc-
tion was assessed 0–3 points (frequency of having trouble
staying awake while driving, eating meals, or engaging in
social activity and frequency of having trouble keeping up
enough enthusiasm to get things done).
We measured height, weight, waist circumference and
blood pressure as physical data of the participants. Body
mass index (BMI) was calculated as weight (kg) divided by
height in meters squared (m2). The waist circumference
was measured with participants standing up straight, at a
navel level with light expiration. When adiposity was
Table 1 Characteristics of participants
Male (n = 549) Female (n = 932) p value
Age, y 57.1 ± 14.4 57.9 ± 13.6 0.246
BMI, kg/m2 23.6 ± 2.9 22.9 ± 3.4 <0.001
Sleep duration, min/day 461 ± 76 430 ± 68 <0.001
Current drinker 402 (73.2) 222 (23.8) <0.001
Current smoker 198 (36.1) 89 (9.5) <0.001
Exercise habits 156 (28.4) 244 (26.2) 0.349
Depression 83 (15.1) 218 (23.4) <0.001
Metabolic syndrome 105 (19.1) 63 (6.8) <0.001
Abdominal obesity 262 (47.7) 187 (20.1) <0.001
Hypertension 322 (58.7) 476 (51.1) 0.005
Impaired fasting glucose 79 (14.4) 70 (7.5) <0.001
Dyslipidemia 154 (28.1) 190 (23.4) 0.001
Global PSQI score, points 2.8 ± 2.0 3.4 ± 2.3 <0.001
0-1 152 (27.7) 191 (20.5)
2-3 231 (42.1) 364 (39.1)
4-5 114 (20.8) 244 (26.2)
6-7 34 (6.2) 80 (8.6)
8-9 12 (2.2) 31 (3.3)
10-11 4 (0.7) 14 (1.5)
12-13 2 (0.4) 5 (0.5)
14-15 0 (0.0) 3 (0.3)
16-21 0 (0.0) 0 (0.0)
Data are presented as mean ± standard deviation or number (%).
The chi-square statistical test for nominal variables and one-way analysis of
variance for continuous variables were performed to assess whether there
were significant differences among the groups stratified by sex.
Abbreviations: BMI, body mass index.
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dle point of costal inferior border and anterior intestinal
portal osteophyte. Blood pressure was measured as systolic
and diastolic blood pressure on the arm in a seated pos-
ition by an automatic sphygmomanometer.
We also collected venous blood samples from the partic-
ipants when they were fasting on the day of investigation.
Determination of serum concentration of triglyceride, high
density lipoprotein cholesterol (HDL-C) and glucose were
performed with enzyme assay by the Mitsubishi Chemical
Medience Corporation.
Metabolic syndrome was defined by eight medical societies
(Committee to Evaluate Diagnostic Standards for Metabolic
Syndrome) in Japan [19]. Metabolic syndrome consists of
four criteria as follows: (1) abdominal obesity, waist circum-
ference of 85 cm or greater in male, 90 cm or greater in fe-
male; (2) hypertension, systolic blood pressure of 130 mmHg
or greater, or diastolic blood pressure of 85 mmHg or
greater, or use of antihypertensive drugs; (3) impaired glu-
cose tolerance, serum glucose of 110 mg/dL or greater, or
use of antidiabetic drugs; and (4) dyslipidemia, serum trigly-
ceride of 150 mg/dL or greater, or serum HDL-C of less than
40 mg/dL, or use of antidyslipidemic drugs. Diagnosis of
metabolic syndrome was done when the participants have
abdominal obesity and meet two or more other criteria.
Statistical analysis
All statistical analyses were conducted separately by gender
because some previous studies had suggested gender differ-
ences of sleep outcomes [13]. Unpaired t-test was used to
determine differences of age, BMI, sleep duration and glo-
bal PSQI score. Chi-square test was used to test differences
of drinking habit, smoking habit, exercise habit, metabolic
syndrome, abdominal obesity, hypertension, impaired glu-
cose tolerance and dyslipidemia. Analysis of covariance
(ANCOVA) for continuous variables was performed to de-
termine any significant differences among groups of non-
metabolic syndrome and metabolic syndrome after adjusted
by age, drinking habit, smoking habit, working hours per
week, exercise habit and depression. Logistic regression
analysis was conducted to assess relationships of sleep dis-
order diagnosed with global PSQI score and other 7 ele-
ments with metabolic syndrome after adjusted by plausible
confounding factors such as age, lifestyles including smok-
ing habit, drinking habit, exercise habit, working hours per
week and depression. Odds ratios were calculated from lo-
gistic regression analysis with 95% confidence intervals.
All analyses were performed using SPSS 12.0 J for
Windows, and p < 0.05 was considered to be statisti-
cally significant.
Results
Characteristics of the participants are shown in Table 1. Of
1481 participants, 549 (37.1%) were males and 932 (62.9%)were females. Mean of BMI in males was 23.6 kg/m2 and
22.9 kg/m2 in females, and was thus significantly higher in
males than females. Mean of sleep duration was 461 mi-
nutes in males and 430 minutes in females, and thus sig-
nificantly longer in males than females. Proportion of the
participants with drinking habit and smoking habit were
greater in males than in females. Prevalence of depression
was lower in males than in females. Prevalence of metabolic
syndrome, abdominal obesity, hypertension, impaired glu-
cose tolerance and dyslipidemia was greater in males than
in females. Global PSQI score was significantly higher in fe-
males than males. Among all participants, 52 of males
(9.5% of total males) and 133 of females (14.3% of total fe-
males) scored 6 or more.
Table 2 shows the significant differences among the
groups of non-metabolic syndrome and metabolic syn-
drome. In males with metabolic syndrome, the means of
global PSQI score, sleep latency score, sleep duration score
and sleep disturbance score were significantly higher than
those without metabolic syndrome. In females with meta-
bolic syndrome, the means of global PSQI score, sleep
Table 2 Comparison of each PSQI score between the
groups of without metabolic syndrome and with
metabolic syndrome
Without MetS With MetS p value
Male
Global PSQI score 2.69 ± 0.09 3.44 ± 0.19 <0.001
Subjective sleep quality 0.76 ± 0.03 0.87 ± 0.06 0.066
Sleep latency 0.43 ± 0.03 0.63 ± 0.07 0.009
Sleep duration 0.49 ± 0.03 0.69 ± 0.07 0.009
Habitual sleep efficiency 0.02 ± 0.01 0.05 ± 0.02 0.061
Sleep disturbance 0.54 ± 0.02 0.67 ± 0.05 0.025
Use of sleep medication 0.10 ± 0.02 0.11 ± 0.05 0.744
Daytime dysfunction 0.36 ± 0.03 0.41 ± 0.06 0.408
Female
Global PSQI score 3.27 ± 0.07 4.78 ± 0.28 <0.001
Subjective sleep quality 0.81 ± 0.02 0.90 ± 0.08 0.081
Sleep latency 0.53 ± 0.03 1.04 ± 0.10 <0.001
Sleep duration 0.78 ± 0.03 0.88 ± 0.10 0.323
Habitual sleep efficiency 0.01 ± 0.01 0.21 ± 0.03 <0.001
Sleep disturbance 0.57 ± 0.02 0.79 ± 0.07 0.002
Use of sleep medication 0.16 ± 0.02 0.45 ± 0.08 0.001
Daytime dysfunction 0.41 ± 0.02 0.51 ± 0.08 0.231
Data are presented as mean ± standard error.
One-way analysis of covariance for continuous variables were performed to assess
whether there were significant differences among the groups of non-metabolic
syndrome and metabolic syndrome after adjusted for age, current drinking status,
current smoking status, working hours per a week, exercise habits and depression.
Abbreviations: Mets, metabolic syndrome. PSQI, Pittsburgh sleep quality index.
Table 3 Odds ratio of metabolic syndrome by PSQI and
its components in males
Score n OR 95% CI p value
Global PSQI score ≤5 497 1.00 (reference)
≥6 52 2.37 (1.23-4.58) 0.010
Subjective sleep quality 0 173 1.00 (reference)
1 323 1.14 (0.69-1.88) 0.603
2 52 1.88 (0.87-4.07) 0.107
3 1 - -
Sleep latency 0 353 1.00 (reference)
1 152 1.54 (0.95-2.51) 0.082
2 29 2.65 (1.14-6.15) 0.023
3 15 1.89 (0.58-6.21) 0.293
Sleep duration 0 329 1.00 (reference)
1 151 1.89 (1.14-3.13) 0.014
2 66 1.65 (0.81-3.38) 0.172
3 3 14.08 (1.21-163.85) 0.035
Habitual sleep efficiency 0 537 1.00 (reference)
1 11 1.90 (0.52-6.97) 0.334
2 1 -
3 0 -
Sleep disturbance 0 251 1.00 (reference)
1 285 1.76 (1.09-2.86) 0.022
2 12 2.44 (0.64-9.22) 0.190
3 1 -
Use of sleep medication 0 528 1.00 (reference)
1 3 0.00 (0.00- ) 0.999
2 3 1.40 (0.12-16.48) 0.791
3 15 1.17 (0.36-3.75) 0.797
Daytime dysfunction 0 375 1.00 (reference)
1 152 1.61 (0.99-2.62) 0.055
2 17 0.30 (0.18-2.37) 0.255
3 5 1.75 (0.18-16.84) 0.628
Data are presented as adjusted odds ratio (95% Confidence Interval) of
metabolic syndrome.
Logistic regression analysis was conducted after adjusted for age, current
drinking status, current smoking status, working hours per a week, exercise
habits and depression.
Abbreviations: OR, odds ratio. CI, confidence interval. PSQI, Pittsburgh sleep
quality index.
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turbance score and use of sleep medication score were
significantly higher compared to those without meta-
bolic syndrome.
The results of logistic regression analysis on associations
between sleep disorder (global PSQI and its components)
and metabolic syndrome after adjusted for age, lifestyle and
depression are shown in Tables 3 and 4. In males, odds ra-
tio of metabolic syndrome among those with the global
PSQI score of 6 or more was 2.37 in contrast with those
whose score was 5 or less. In females, odds ratio of meta-
bolic syndrome among those with the global PSQI score of
6 or more was 2.71 in contrast with those with global PSQI
score of 5 or less. Our results showed no associations be-
tween subjective sleep quality and metabolic syndrome in
males and females. In males, the odds ratio of it among
those with sleep latency score of 2 was 2.65 in contrast with
those with 0. In females, the odds ratios of it among those
with sleep latency score of 2 and 3 were 3.82 and 5.95, re-
spectively, in contrast with those of 0. In males, the odds
ratios among those with sleep duration score of 1 (6–7
hours/day) and 3 (<5 hours/day) were 1.89 and 14.08, re-
spectively, in contrast with those of 0 (>7 hours/day).Results in females showed no association between sleep
duration and metabolic syndrome. Males and females had
no association between habitual sleep efficiency and meta-
bolic syndrome. In males, the odds ratio among those with
sleep disturbance score of 1 was 1.76 in contrast with those
of 0. In females, the odds ratios among those with sleep dis-
turbance score of 1 and 2 were 2.43 and 3.84, respectively,
in contrast with those of 0. Males had no association be-
tween use of sleep medication score and metabolic syn-
drome. In females, the odds ratios among those with use of
Table 4 Odds ratio of metabolic syndrome by PSQI and
its components in females
Score n OR 95% CI p value
Global PSQI score ≤5 799 1.00 (reference)
≥6 133 2.71 (1.45-5.07) 0.002
Subjective sleep quality 0 290 1.00 (reference)
1 530 1.41 (0.77-2.58) 0.263
2 108 1.55 (0.59-4.08) 0.378
3 4 2.96 (0.26-34.11) 0.385
Sleep latency 0 555 1.00 (reference)
1 261 1.65 (0.86-3.16) 0.131
2 85 3.82 (1.81-8.09) <0.001
3 31 5.95 (2.17-16.34) 0.001
Sleep duration 0 411 1.00 (reference)
1 324 0.96 (0.50-1.85) 0.904
2 186 1.57 (0.81-3.06) 0.185
3 11 1.20 (0.13-10.91) 0.870
Habitual sleep efficiency 0 915 1.00 (reference)
1 11 3.96 (0.96-16.34) 0.057
2 4 - 0.999
3 2 10.42 (0.61-176.68) 0.105
Sleep disturbance 0 412 1.00 (reference)
1 492 2.43 (1.26-4.69) 0.008
2 27 3.84 (1.17-12.65) 0.027
3 1 -
Use of sleep medication 0 861 1.00 (reference)
1 18 3.81 (1.15-12.68) 0.029
2 10 1.12 (0.13-9.86) 0.916
3 43 3.10 (1.32-7.30) 0.009
Daytime dysfunction 0 609 1.00 (reference)
1 263 1.12 (0.61-2.06) 0.710
2 52 0.75 (0.16-3.52) 0.718
3 8 6.27 (1.24-31.79) 0.027
Data are presented as adjusted odds ratio (95% Confidence Interval) of
metabolic syndrome.
Logistic regression analysis was conducted after adjusted for age, current
drinking status, current smoking status, working hours per a week, exercise
habits and depression.
Abbreviations: OR, odds ratio. CI, confidence interval. PSQI, Pittsburgh sleep
quality index
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week) were 3.81 and 3.10, respectively, in contrast with
those of 0 (no use of medication). Males had no association
between daytime dysfunction and metabolic syndrome. In
females, the odds ratio among those with daytime dysfunc-
tion score of 3 was 6.27 in contrast with those of 0.
Discussion
In previous studies, assessment of sleep duration has been
mainly used to evaluate the status of sleep. However,measuring sleep duration only is insufficient for under-
standing global sleep status, which consist of not only
sleep duration but also quality and other various factors.
These sleep-related factors include quantitative and quali-
tative variables, which has made sleep status difficult to
understand. Taking both aspects into consideration, our
study used PSQI scale to evaluate global sleep status. We
examined the associations of metabolic syndrome with
global PSQI scale and its components (sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep dis-
turbance, use of sleep medication and daytime dysfunction).
Our results showed significant associations of metabolic
syndrome with global PSQI score, poor sleep quality, pro-
longed sleep latency, short sleep duration, sleep disturbance
and daytime dysfunction. So far no studies have reported
the association between metabolic syndrome and PSQI
components. Especially, global sleep status that in-
cluded sleep latency, habitual sleep efficiency, sleep dis-
turbance and daytime dysfunction has rarely received
attention in scientific research. Thus, the current study
could provide novel findings which suggest the relation-
ship between sleep status and metabolic syndrome.
Kazman et al. have reported that there has been no asso-
ciation between global PSQI score and metabolic syn-
drome [20]. On the other hand, some studies have
reported that the global PSQI score has been associated
with metabolic syndrome [15,16]. Thus, the association
between sleep and metabolic syndrome has various as-
pects. One of the possible reasons for such variations is
that participants of those studies include clinical patients
and healthy individuals with limited range of age. Add-
itionally, in previous studies, the confounding factors such
as lifestyles including drinking habits and exercise habit
have not been sufficiently adjusted. Data obtained in this
study was analyzed separately by gender and adjusted by
age, drinking habit, smoking habit, exercise habit and de-
pression. The participants of this study were all adults
from Japanese general population, and the mean of global
PSQI score with metabolic syndrome and non-metabolic
syndrome was 5 or less (no sleep disorder). However, we
also indicated that global PSQI score with metabolic syn-
drome was higher than those with non-metabolic syn-
drome. Consequently, those who scored high global PSQI
score would be at high risk of metabolic syndrome even
though they have no sleep disorder.
What we could underline was that we examined the
correlation between PSQI components and metabolic
syndrome. Many previous studies assessed sleep status
by global PSQI score only, whereas our study assessed
it by PSQI components as well as global score. This
study indicated the PSQI components including poor
sleep quality, prolonged sleep latency, short sleep dur-
ation and sleep disturbance were associated with meta-
bolic syndrome, which showed importance of sleep
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derstanding of sleep.
The mechanism of the relationship between sleep dis-
order and metabolic syndrome has not been clarified due
to lack of confirming evidence. Sleep rhythm is regulated
by hypothalamus [21]. Hypothalamic-pituitary- adrenal axis
(HPA) is involved with metabolic syndrome [22], and acti-
vated HPA affects sleep disorder [23]. Poor sleep quality
and prolonged sleep latency activate HPA, enhancing stress
hormone secretion such as cortisol and catecholamine
[24,25]. These excess secretions finally leads to increased
risk of metabolic syndrome. Sympathomimetic state in-
duced by poor sleep quality reduces leptin level and ele-
vates ghrelin level, which is also related with obesity [4,26].
Additionally, Nguyen-Rodriguez ST et al. have reported
that sleep latency has been associated with emotional eating
[27]. From the mechanisms mentioned above, it is likely
that poor sleep quality, prolonged sleep latency and sleep
disturbance increase a risk of metabolic syndrome through
sympathomimetic state and emotional eating.
In the present study, short sleep duration was associated
with metabolic syndrome in males, but not in females.
Some previous studies reported the association between
sleep duration and metabolic syndrome [10,28,29]. Our re-
sults showed sleep duration was correlated with other
PSQI components. Therefore, influence of sleep duration
on metabolic syndrome, which was observed in previous
studies, was considered smaller than that of global sleep
quality.
In this study, habitual sleep efficiency, use of sleep
medication and daytime dysfunction showed significant
odds ratios, although lacking in reliability. As the partici-
pants of the present study were recruited from general
population, there were a few individuals who had appar-
ent sleep disorder, including poor habitual efficiency, use
of sleep medication and daytime dysfunction. Thus, we
need to increase the number of the participants to clarify
the relationship between them.
Most previous studies reported that short sleep duration
was associated with obesity, hypertension, impaired glu-
cose tolerance and dyslipidemia [10,28,29]. Our study has
some advantages. We were able to consider the compre-
hensive relationships taking lifestyles and depression into
account. On the other hand, we were able to evaluate not
only the sleep duration but also the comprehensive sleep
status including sleep quality, sleep latency, habitual sleep
efficiency and sleep disturbance.
However, our study has some limitations. First, this
study was limited by the cross-sectional design. Thus,
the causal relationship between metabolic syndrome and
sleep status could not be revealed. Second, we evaluated
sleep-related factors and lifestyles by self-reported brief
questionnaires. Sleep evaluation by combining polysom-
nography and self-report questionnaires may have led toa different result. Additionally, we could have evaluated
them with brief questionnaires because complex ques-
tionnaires might make the participants confused. Al-
though PSQI focused on short sleep induced by sleep
disturbance, short sleepers were a minority in this study.
This might tend to give the weaker association between
sleep duration and metabolic syndrome compared with
previous studies. Third, this study did not exclude ob-
structive sleep apnea. Obstructive sleep apnea triggers im-
paired sleep quality and sleep fragmentation. Furthermore,
it enhances stress hormone secretion. Fourth, the partici-
pants of this study took part in a screening project which
was conducted by us. So, we did not deny that there is
sampling bias among the participants. Fifth, metabolic
syndrome is associated with eating habit, but we did not
investigate this because we did not interview the subjects
or have suitable questionnaires about eating habit.
Conclusions
Our results indicated that high global PSQI score was re-
lated with high odds ratio of metabolic syndrome in general
population. Even when global PSQI score is 5 and less,
there is a high odds ratio of metabolic syndrome if they
scored high global PSQI score. The PSQI components in-
cluding poor sleep quality, prolonged sleep latency, short
sleep duration and sleep disturbance were also associated
with metabolic syndrome.
Abbreviation
PSQI: Pittsburgh sleep quality index.
Competing interests
This was not an industry-supported study. This study was supported by a
Grant-in-Aid for Young Scientists from The Ministry of Education, Culture,
Sports, Science and Technology (MEXT) (21792291) and a Health Science
Research Grant from the ministry of Health, Labour and Welfare of the
Japanese Government (N20120199). All authors declare that they have no
competing interests.
Authors’ contributions
NO drafted the manuscript and performed the descriptive data analysis. MM
participated in the study design and coordination and helped draft the
manuscript. IT participated in study design, helped draft the manuscript and
reviewed the manuscript for important intellectual content. KS participated in
study design, helped draft the manuscript and reviewed the manuscript for
important intellectual content. SS participated in the study, helped draft the
manuscript and reviewed the manuscript for important intellectual content. NA
participated in the study, helped draft the manuscript and reviewed the
manuscript for important intellectual content. TU participated in the study
design, helped draft the manuscript and reviewed the manuscript for important
intellectual content. SN conceived of the study, participated in its design,
analysis and interpretation of data and reviewed the manuscript for important
intellectual content. All authors read and approved the final manuscript.
Acknowledgment
We wish to express our gratitude to Takashi Ohida; MD, Yoshitaka Kaneita;
MD (Department of Public Health, School of Medicine, Nihon University) and
Miya Nishimura; PhD (Hirosaki University Graduate School of Health Sciences)
for their generous help and support in this study. This study was supported
by a Grant-in-Aid for Young Scientists from The Ministry of Education,
Culture, Sports, Science and Technology (MEXT) (21792291) and a Health
Science Research Grant from the ministry of Health, Labour and Welfare of
the Japanese Government (N20120199).
Okubo et al. BMC Public Health 2014, 14:562 Page 7 of 7
http://www.biomedcentral.com/1471-2458/14/562Author details
1Department of Social Medicine, Hirosaki University Graduate School of
Medicine, 5, Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. 2Department of
Medical Informatics, Hirosaki University Graduate School of medicine, 5,
Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. 3Department of Faculty of
Pharmacy, Meijo University, Yagotoyama 150, Tenpaku-ku, Nagoya, Aichi
468-8503, Japan.
Received: 16 October 2013 Accepted: 23 May 2014
Published: 5 June 2014
References
1. Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC: The metabolic
syndrome and its components and the long-term risk of death in
patients with coronary heart disease. Am Heart J 2006, 151(2):514–521.
2. Tillin T, Forouhi NG, McKeigue PM, Chaturvedi N: The role of diabetes and
components of the metabolic syndrome in stroke and coronary heart
disease mortality in U.K. white and African-Caribbean populations.
Diabetes Care 2006, 29(9):2127–2129.
3. Kadota A, Hozawa A, Okamura T, Kadowak T, Nakmaura K, Murakami Y,
Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H,
NIPPON DATA Research Group: Relationship between metabolic risk
factor clustering and cardiovascular mortality stratified by high blood
glucose and obesity: NIPPON DATA90, 1990–2000. Diabetes Care 2007,
30(6):1533–1538.
4. Taheri S, Lin L, Austin D, Young T, Mignot E: Short sleep duration is
associated with reduced leptin, elevated ghrelin, and increased body
mass index. PLoS Med 2004, 1(3):e62.
5. Yaggi HK, Araujo AB, McKinlay JB: Sleep duration as a risk factor for the
development of type 2 diabetes. Diabetes Care 2006, 29(3):657–661.
6. Gottlieb DJ, Redline S, Nieto FJ, Baldwin CM, Newman AB, Resnick HE,
Punjabi NM: Association of usual sleep duration with hypertension: the
Sleep Heart Health Study. Sleep 2006, 29(8):1009–1014.
7. Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, Hu FB:
A prospective study of sleep duration and coronary heart disease in
women. Arch Intern Med 2003, 163(2):205–209.
8. Wolff B, Volzke H, Schwahn C, Robinson D, Kessler C, John U: Relation of
self-reported sleep duration with carotid intima-media thickness in a
general population sample. Atherosclerosis 2008, 196(2):727–732.
9. Portaluppi F, Vergnani L, Manfredini R, Fersini C: Endocrine mechanisms of
blood pressure rhythms. Ann N Y Acad Sci 1996, 783:113–131.
10. Hall MH, Muldoon MF, Jennings JR, Buysse DJ, Flory JD, Manuck SB: Self-
reported sleep duration is associated with the metabolic syndrome in
midlife adults. Sleep 2008, 31(5):635–643.
11. Ferrie JE, Shipley MJ, Cappuccio FP, Brunner E, Miller MA, Kumari M, Marmot
MG: A prospective study of change in sleep duration: associations with
mortality in the Whitehall II cohort. Sleep 2007, 30(12):1659–1666.
12. Eguchi K, Pickering TG, Schwartz JE, Hoshide S, Ishikawa J, Ishikawa S,
Shimada K, Kario K: Short sleep duration as an independent predictor of
cardiovascular events in Japanese patients with hypertension. Arch Intern
Med 2008, 168(20):2225–2231.
13. Doi Y, Minowa M, Okawa M, Uchiyama M: Prevalence of sleep disturbance
and hypnotic medication use in relation to sociodemographic factors in
the general Japanese adult population. J Epidemiol 2000, 10(2):79–86.
14. Kaneita Y, Uchiyama M, Yoshiike N, Ohida T: Associations of usual sleep
duration with serum lipid and lipoprotein levels. Sleep 2008, 31(5):645–652.
15. Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ: The Association
Between Self-Reported Sleep Quality and Overweight in A Chinese
Population. Obesity 2013, 21(3):486–492.
16. Jennings JR, Muldoon MF, Hall M, Buysse DJ, Manuck SB: Self-reported
sleep quality is associated with the metabolic syndrome. Sleep 2007,
30(2):219–223.
17. Radloff L: A Self-Report Depression Scale for Research in the General
Population. Psychological Measurement 1977, 1(3):385–401.
18. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The
Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice
and research. Psychiatry Res 1989, 28(2):193–213.
19. Committee for the Criteria of Metabolic Syndrome: Definition and the
diagnostic standard for metabolic syndrome–Committee to Evaluate
Diagnostic Standards for Metabolic Syndrome. Nihon Naika Gakkai Zasshi
2005, 94(4):794–809. in Japanese.20. Kazman JB, Abraham PA, Zeno SA, Poth M, Deuster PA: Self-reported sleep
impairment and the metabolic syndrome among African Americans.
Ethn Dis 2012, 22(4):410–415.
21. Jan JE, Reiter RJ, Wasdell MB, Bax M: The role of the thalamus in sleep,
pineal melatonin production, and circadian rhythm sleep disorders.
J Pineal Res 2009, 46(1):1–7.
22. Cagampang FR, Poore KR, Hanson MA: Developmental origins of the
metabolic syndrome: body clocks and stress responses. Brain Behav
Immun 2011, 25(2):214–220.
23. Vgontzas AN, Chrousos GP: Sleep, the hypothalamic-pituitary-adrenal axis,
and cytokines: multiple interactions and disturbances in sleep disorders.
Endocrinol Metab Clin N Am 2002, 31(1):15–36.
24. Balbo M, Leproult R, Van Cauter E: Impact of sleep and its disturbances on
hypothalamo-pituitary-adrenal axis activity. Int J Endocrinol 2010,
2010:759234.
25. Spiegel K, Leproult R, Van Cauter E: Impact of sleep debt on metabolic
and endocrine function. Lancet 1999, 354(9188):1435–1439.
26. Spiegel K, Tasali E, Penev P, Van Cauter E: Brief communication: Sleep
curtailment in healthy young men is associated with decreased leptin
levels, elevated ghrelin levels, and increased hunger and appetite.
Ann Intern Med 2004, 141(11):846–850.
27. Nguyen-Rodriguez ST, McClain AD, Spruijt-Metz D: Anxiety mediates the
relationship between sleep onset latency and emotional eating in
minority children. Eat Behav 2010, 11(4):297–300.
28. Santos AC, Ebrahim S, Barros H: Alcohol intake, smoking, sleeping hours,
physical activity and the metabolic syndrome. Prev Med 2007, 44(4):328–334.
29. Katano S, Nakamura Y, Nakamura A, Murakami Y, Tanaka T, Takebayashi T,
Okayama A, Miura K, Okamura T, Ueshima H, HIPOP-OHP Research Group:
Relationship between sleep duration and clustering of metabolic
syndrome diagnostic components. Diabetes, Metabolic Syndrome and
Obesity : Targets and Therapy 2011, 4:119–125.
doi:10.1186/1471-2458-14-562
Cite this article as: Okubo et al.: Relationship between self-reported
sleep quality and metabolic syndrome in general population. BMC Public
Health 2014 14:562.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
